PositiveID Corporation Wins Gold at Connected World Value Chain Awards for Its iglucose Mobile Health Solution for Diabetes Management
PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By wirelessly communicating data from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals. This makes it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose is compatible with leading FDA-cleared glucometers and does not require the use of a cell phone or a wireless plan.
"The 2012 winners represent successful implementations in home health, education, emergency response, tracking, and even the prevention of distracted driving. This is a great illustration as to how M2M technology and connected devices can be relied upon to not only make our lives more convenient and efficient, but much safer and responsible," says Peggy Smedley, editorial director, Connected World.
William J. Caragol, Chairman and CEO of PositiveID, said, "Winning gold at Connected World's Value Chain Awards is another validation of the mobile health community's belief in the value of iglucose."
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour(R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.